var data={"title":"Antiprotozoal therapies","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"topicTitle\">Antiprotozoal therapies</div><dl id=\"topicContributors\"><dt><span> </span>Author:</dt><dd><a href=\"https://www.uptodate.com/contents/antiprotozoal-therapies/contributors\" class=\"contributor contributor_credentials\">Peter F Weller, MD, MACP</a></dd><dt><span> </span>Section Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/antiprotozoal-therapies/contributors\" class=\"contributor contributor_credentials\">Karin Leder, MBBS, FRACP, PhD, MPH, DTMH</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/antiprotozoal-therapies/contributors\" class=\"contributor contributor_credentials\">Elinor L Baron, MD, DTMH</a></dd></dl><p class=\"disclosureLink\"><a href=\"https://www.uptodate.com/contents/antiprotozoal-therapies/contributor-disclosure\" class=\"contributor contributor_credentials\">Contributor Disclosures</a></p><div id=\"reviewProcess\"><span>All topics are updated as new evidence becomes available and our <a href=\"https://www.uptodate.com/home/editorial-policy\" target=\"_blank\" class=\"policy policy_editorialpolicy\">peer review process</a> is complete.</span></div><div id=\"literatureReviewDate\"><span class=\"emphasis\">Literature review current through:</span>&#160;Feb 2018.&#160;&#124;&#160;<span class=\"emphasis\">This topic last updated:</span>&#160;May 26, 2017.</div><div id=\"topicWhatsNewContainer\"></div><div id=\"topicText\"><p class=\"headingAnchor\" id=\"H1\"><span class=\"h1\">INTRODUCTION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Protozoan parasites belong to four distinct groups: the amebae, the flagellates, the ciliates, and the sporozoa. Protozoa are single-celled organisms that replicate by various mechanisms within the infected host. The mechanisms of action of the various agents used to treat protozoan parasites are relatively poorly understood [<a href=\"https://www.uptodate.com/contents/antiprotozoal-therapies/abstract/1\" class=\"abstract_t\">1</a>].</p><p>In the United States, the antiprotozoal drugs <a href=\"topic.htm?path=eflornithine-united-states-availability-of-intravenous-preparation-limited-to-cdc-and-who-distribution-programs-drug-information\" class=\"drug drug_general\">eflornithine</a>, <a href=\"topic.htm?path=benznidazole-united-states-available-via-cdc-drug-service-investigational-drug-ind-protocol-only-drug-information\" class=\"drug drug_general\">benznidazole</a>, melarsoprol, nifurtimox, <a href=\"topic.htm?path=sodium-stibogluconate-united-states-available-via-cdc-drug-service-investigational-drug-ind-protocol-only-drug-information\" class=\"drug drug_general\">sodium stibogluconate</a>, and <a href=\"topic.htm?path=suramin-united-states-available-via-cdc-drug-service-investigational-drug-ind-protocol-only-drug-information\" class=\"drug drug_general\">suramin</a> are available through the Centers for Disease Control and Prevention (CDC) Drug Service, Atlanta, GA 30333 (telephone 404-639-3670; drugservice@cdc.gov).</p><p>Agents with activity against protozoal parasites will be reviewed here; their use for treatment of specific protozoal infections is discussed in detail separately. Antimalarial agents are discussed in detail separately, as are agents with activity against helminths. (See <a href=\"topic.htm?path=antimalarial-drugs-an-overview\" class=\"medical medical_review\">&quot;Antimalarial drugs: An overview&quot;</a> and <a href=\"topic.htm?path=anthelminthic-therapies\" class=\"medical medical_review\">&quot;Anthelminthic therapies&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H2\"><span class=\"h1\">ALBENDAZOLE</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=albendazole-drug-information\" class=\"drug drug_general\">Albendazole</a> binds to tubulin and affects cytoskeletal microtubules and is a well-established therapy treatment of helminthic infections [<a href=\"https://www.uptodate.com/contents/antiprotozoal-therapies/abstract/2\" class=\"abstract_t\">2</a>]. (See <a href=\"topic.htm?path=anthelminthic-therapies\" class=\"medical medical_review\">&quot;Anthelminthic therapies&quot;</a>.)</p><p><a href=\"topic.htm?path=albendazole-drug-information\" class=\"drug drug_general\">Albendazole</a> also has activity against some protozoan infections, including most microsporidial species, particularly <em>Encephalitozoon</em> infections. However, it is not as active against <em>Enterocytozoon bieneusi</em> [<a href=\"https://www.uptodate.com/contents/antiprotozoal-therapies/abstract/3-10\" class=\"abstract_t\">3-10</a>]. (See <a href=\"topic.htm?path=microsporidiosis\" class=\"medical medical_review\">&quot;Microsporidiosis&quot;</a>.)</p><p>Absorption of <a href=\"topic.htm?path=albendazole-drug-information\" class=\"drug drug_general\">albendazole</a> is enhanced by taking it with fatty meals. Albendazole should be taken with fatty foods for treatment of invasive systemic parasitic infections; it should be taken with no food (eg, on an empty stomach) for treatment of intraluminal parasitic infections with no systemic involvement.</p><p class=\"headingAnchor\" id=\"H3\"><span class=\"h1\">ATOVAQUONE</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=atovaquone-drug-information\" class=\"drug drug_general\">Atovaquone</a> is a hydroxynaphthoquinone agent active against several protozoan parasites [<a href=\"https://www.uptodate.com/contents/antiprotozoal-therapies/abstract/11\" class=\"abstract_t\">11</a>].</p><p>For the treatment of <em>Pneumocystis jirovecii</em> (formerly <em>carinii</em>) pneumonia (PCP), <a href=\"topic.htm?path=atovaquone-drug-information\" class=\"drug drug_general\">atovaquone</a> is well tolerated but less effective than <a href=\"topic.htm?path=pentamidine-drug-information\" class=\"drug drug_general\">pentamidine</a> or <a href=\"topic.htm?path=trimethoprim-sulfamethoxazole-co-trimoxazole-drug-information\" class=\"drug drug_general\">trimethoprim-sulfamethoxazole</a> (TMP-SMX). Atovaquone is an alternative agent for prophylaxis against PCP for patients who are unable to tolerate TMP-SMX. (See <a href=\"topic.htm?path=epidemiology-clinical-manifestations-and-diagnosis-of-pneumocystis-pneumonia-in-hiv-uninfected-patients\" class=\"medical medical_review\">&quot;Epidemiology, clinical manifestations, and diagnosis of Pneumocystis pneumonia in HIV-uninfected patients&quot;</a> and <a href=\"topic.htm?path=treatment-and-prevention-of-pneumocystis-infection-in-hiv-infected-patients\" class=\"medical medical_review\">&quot;Treatment and prevention of Pneumocystis infection in HIV-infected patients&quot;</a>.)</p><p>Atovaquone-pyrimethamine is an alternative agent for treatment and long-term maintenance therapy of <em>Toxoplasma </em>encephalitis in AIDS patients intolerant of sulfonamides. (See <a href=\"topic.htm?path=overview-of-prevention-of-opportunistic-infections-in-hiv-infected-patients\" class=\"medical medical_review\">&quot;Overview of prevention of opportunistic infections in HIV-infected patients&quot;</a> and <a href=\"topic.htm?path=toxoplasmosis-in-hiv-infected-patients\" class=\"medical medical_review\">&quot;Toxoplasmosis in HIV-infected patients&quot;</a>.)</p><p><a href=\"topic.htm?path=atovaquone-and-proguanil-drug-information\" class=\"drug drug_general\">Atovaquone-proguanil</a> may be used for malaria chemoprophylaxis and is also effective in the treatment of <em>Plasmodium falciparum</em> malaria. (See <a href=\"topic.htm?path=antimalarial-drugs-an-overview\" class=\"medical medical_review\">&quot;Antimalarial drugs: An overview&quot;</a>.)</p><p>Atovaquone-azithromycin may be used for treatment of babesiosis. (See <a href=\"topic.htm?path=babesiosis-clinical-manifestations-and-diagnosis\" class=\"medical medical_review\">&quot;Babesiosis: Clinical manifestations and diagnosis&quot;</a>.)</p><p><a href=\"topic.htm?path=atovaquone-drug-information\" class=\"drug drug_general\">Atovaquone</a> suspension is twice as well absorbed as the tablet form, and consumption of atovaquone with a fatty meal enhances absorption [<a href=\"https://www.uptodate.com/contents/antiprotozoal-therapies/abstract/12\" class=\"abstract_t\">12</a>].</p><p class=\"headingAnchor\" id=\"H4\"><span class=\"h1\">BENZNIDAZOLE</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=benznidazole-united-states-available-via-cdc-drug-service-investigational-drug-ind-protocol-only-drug-information\" class=\"drug drug_general\">Benznidazole</a> is a nitroimidazole derivative with activity against <em>Trypanosoma cruzi</em> trypomastigotes and amastigotes. Side effects include rash, nausea, and peripheral neuritis. (See <a href=\"topic.htm?path=chagas-disease-antitrypanosomal-drug-therapy\" class=\"medical medical_review\">&quot;Chagas disease: Antitrypanosomal drug therapy&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H5\"><span class=\"h1\">EFLORNITHINE</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=eflornithine-united-states-availability-of-intravenous-preparation-limited-to-cdc-and-who-distribution-programs-drug-information\" class=\"drug drug_general\">Eflornithine</a> inhibits parasite growth by selective and irreversible inhibition of ornithine carboxylase, an enzyme required for cellular proliferation and differentiation [<a href=\"https://www.uptodate.com/contents/antiprotozoal-therapies/abstract/13,14\" class=\"abstract_t\">13,14</a>]. It is effective in the early and late central nervous system stage of infections with <em>Trypanosoma brucei gambiense </em>but not <em>T. b. rhodesiense</em>. (See <a href=\"topic.htm?path=african-trypanosomiasis-clinical-manifestations-diagnosis-and-treatment\" class=\"medical medical_review\">&quot;African trypanosomiasis: Clinical manifestations, diagnosis, and treatment&quot;</a>.)</p><p>Frequent side effects include diarrhea, anemia, leukopenia, and hair loss.</p><p class=\"headingAnchor\" id=\"H6\"><span class=\"h1\">FUMAGILLIN</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Fumagillin is an antibiotic released by <em>Aspergillus fumigatus</em>. The mechanism of action of fumagillin has not been established, but the drug can suppress proliferation of microsporidia in vitro [<a href=\"https://www.uptodate.com/contents/antiprotozoal-therapies/abstract/15\" class=\"abstract_t\">15</a>].</p><p>Topical fumagillin therapy has been successful in several cases of microsporidial keratoconjunctivitis in patients with AIDS. Fumagillin has also been used to treat intestinal <em>E. bieneusi</em> infections in immunocompromised patients; neutropenia and thrombocytopenia are common complications. (See <a href=\"topic.htm?path=microsporidiosis\" class=\"medical medical_review\">&quot;Microsporidiosis&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H7\"><span class=\"h1\">FURAZOLIDONE</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Furazolidone is a nitrofuran derivative used as an alternative drug for giardiasis. Adverse effects include nausea, vomiting, and allergic reactions [<a href=\"https://www.uptodate.com/contents/antiprotozoal-therapies/abstract/16\" class=\"abstract_t\">16</a>]. The drug is a monoamine oxidase inhibitor and also causes a disulfiram-like reaction when taken with alcohol. Furazolidone is not bitter (unlike other drugs for giardiasis) and is available in a liquid form useful for young children. (See <a href=\"topic.htm?path=giardiasis-treatment-and-prevention\" class=\"medical medical_review\">&quot;Giardiasis: Treatment and prevention&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H8\"><span class=\"h1\">IODOQUINOL</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=iodoquinol-drug-information\" class=\"drug drug_general\">Iodoquinol</a> is a halogenated oxyquinolone used for treatment of noninvasive amebiasis and <em>Dientamoeba fragilis </em>and as an alternative for <em>Balantidium coli</em> infection. Adverse effects are uncommon; optic neuritis has been observed when high doses are administered for a prolonged period [<a href=\"https://www.uptodate.com/contents/antiprotozoal-therapies/abstract/17\" class=\"abstract_t\">17</a>]. (See <a href=\"topic.htm?path=intestinal-entamoeba-histolytica-amebiasis\" class=\"medical medical_review\">&quot;Intestinal Entamoeba histolytica amebiasis&quot;</a> and <a href=\"topic.htm?path=dientamoeba-fragilis\" class=\"medical medical_review\">&quot;Dientamoeba fragilis&quot;</a> and <a href=\"topic.htm?path=balantidium-coli-infection\" class=\"medical medical_review\">&quot;Balantidium coli infection&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H9\"><span class=\"h1\">MELARSOPROL</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Melarsoprol is a trivalent arsenical compound used to treat late-stage African trypanosomiasis involving the central nervous system [<a href=\"https://www.uptodate.com/contents/antiprotozoal-therapies/abstract/18\" class=\"abstract_t\">18</a>]. Melarsoprol appears to act by binding to essential thiol groups of trypanosomes, preventing trophozoite multiplication [<a href=\"https://www.uptodate.com/contents/antiprotozoal-therapies/abstract/13,19,20\" class=\"abstract_t\">13,19,20</a>]. Severe adverse effects are common, including myocarditis, encephalopathy, and hypersensitivity reactions [<a href=\"https://www.uptodate.com/contents/antiprotozoal-therapies/abstract/21\" class=\"abstract_t\">21</a>]. (See <a href=\"topic.htm?path=african-trypanosomiasis-clinical-manifestations-diagnosis-and-treatment\" class=\"medical medical_review\">&quot;African trypanosomiasis: Clinical manifestations, diagnosis, and treatment&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H10\"><span class=\"h1\">METRONIDAZOLE</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=metronidazole-drug-information\" class=\"drug drug_general\">Metronidazole</a> is a 5-nitroimidazole with potent activity against several protozoa including <em>Entamoeba histolytica</em>, <em>Giardia duodenalis</em>, and <em>Trichomonas vaginalis</em>. Metronidazole is the drug of choice for giardiasis and intestinal and extraintestinal amebiasis and trichomoniasis. (See <a href=\"topic.htm?path=intestinal-entamoeba-histolytica-amebiasis\" class=\"medical medical_review\">&quot;Intestinal Entamoeba histolytica amebiasis&quot;</a> and <a href=\"topic.htm?path=extraintestinal-entamoeba-histolytica-amebiasis\" class=\"medical medical_review\">&quot;Extraintestinal Entamoeba histolytica amebiasis&quot;</a> and <a href=\"topic.htm?path=giardiasis-treatment-and-prevention\" class=\"medical medical_review\">&quot;Giardiasis: Treatment and prevention&quot;</a> and <a href=\"topic.htm?path=trichomoniasis\" class=\"medical medical_review\">&quot;Trichomoniasis&quot;</a>.)</p><p><a href=\"topic.htm?path=metronidazole-drug-information\" class=\"drug drug_general\">Metronidazole</a> is generally well tolerated; adverse effects include mild abdominal pain, headache, nausea, and metallic taste. It produces a disulfiram-like reaction when taken with alcohol. (See <a href=\"topic.htm?path=metronidazole-an-overview\" class=\"medical medical_review\">&quot;Metronidazole: An overview&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H11\"><span class=\"h1\">NIFURTIMOX</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Nifurtimox is a synthetic nitrofuran compound for treatment of acute <em>T. cruzi</em> infection. The drug has little effect in chronic Chagas disease. (See <a href=\"topic.htm?path=chagas-gastrointestinal-disease\" class=\"medical medical_review\">&quot;Chagas gastrointestinal disease&quot;</a> and <a href=\"topic.htm?path=chagas-heart-disease-treatment-and-prognosis#H372251532\" class=\"medical medical_review\">&quot;Chagas heart disease: Treatment and prognosis&quot;, section on 'T. cruzi infection'</a>.)</p><p>Nifurtimox can be used in combination with <a href=\"topic.htm?path=eflornithine-united-states-availability-of-intravenous-preparation-limited-to-cdc-and-who-distribution-programs-drug-information\" class=\"drug drug_general\">eflornithine</a> or melarsoprol for treatment of African trypanosomiasis due to <em>T. b. gambiense</em>. (See <a href=\"topic.htm?path=african-trypanosomiasis-clinical-manifestations-diagnosis-and-treatment#H4239238\" class=\"medical medical_review\">&quot;African trypanosomiasis: Clinical manifestations, diagnosis, and treatment&quot;, section on 'Nifurtimox combination therapy'</a>.)</p><p>Adverse reactions are common and dose dependent, including nausea, vomiting, insomnia, headache, vertigo, tremor, paresthesias, and convulsions [<a href=\"https://www.uptodate.com/contents/antiprotozoal-therapies/abstract/21\" class=\"abstract_t\">21</a>].</p><p class=\"headingAnchor\" id=\"H12\"><span class=\"h1\">NITAZOXANIDE</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=nitazoxanide-drug-information\" class=\"drug drug_general\">Nitazoxanide</a> is a nitrothiazolyl-salicylamide derivative useful for treatment diarrhea due to <em>Cryptosporidium parvum</em> in children and for the treatment of giardiasis in children and adults [<a href=\"https://www.uptodate.com/contents/antiprotozoal-therapies/abstract/22\" class=\"abstract_t\">22</a>]. It is generally well tolerated. (See <a href=\"topic.htm?path=giardiasis-treatment-and-prevention\" class=\"medical medical_review\">&quot;Giardiasis: Treatment and prevention&quot;</a>.)</p><p><a href=\"topic.htm?path=nitazoxanide-drug-information\" class=\"drug drug_general\">Nitazoxanide</a> has not been shown to be more effective than placebo in HIV-infected patients; prolonged therapy at higher doses may be required. (See <a href=\"topic.htm?path=epidemiology-clinical-manifestations-and-diagnosis-of-cryptosporidiosis\" class=\"medical medical_review\">&quot;Epidemiology, clinical manifestations, and diagnosis of cryptosporidiosis&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H13\"><span class=\"h1\">PAROMOMYCIN</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=paromomycin-drug-information\" class=\"drug drug_general\">Paromomycin</a> is an oral poorly absorbed aminoglycoside. It is used as a secondary drug for treatment of noninvasive amebiasis. (See <a href=\"topic.htm?path=intestinal-entamoeba-histolytica-amebiasis\" class=\"medical medical_review\">&quot;Intestinal Entamoeba histolytica amebiasis&quot;</a>.)</p><p>It may also be used for the treatment of giardiasis during pregnancy when the disease is not severe enough to require definitive therapy with <a href=\"topic.htm?path=metronidazole-drug-information\" class=\"drug drug_general\">metronidazole</a> or quinacrine. (See <a href=\"topic.htm?path=giardiasis-treatment-and-prevention\" class=\"medical medical_review\">&quot;Giardiasis: Treatment and prevention&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H14\"><span class=\"h1\">PENTAMIDINE</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=pentamidine-drug-information\" class=\"drug drug_general\">Pentamidine</a> isethionate is an aromatic diamine compound active against <em>Pneumocystis</em> and several protozoal pathogens including <em>Leishmanii</em> spp and <em>T. b. gambiense </em>[<a href=\"https://www.uptodate.com/contents/antiprotozoal-therapies/abstract/23\" class=\"abstract_t\">23</a>]. Adverse reactions of parenteral pentamidine are common, including reversible nephrotoxicity, acute hypotension, pancreatitis, hypoglycemia, cardiac arrhythmias, blood dyscrasias, and sterile abscesses at the injection site [<a href=\"https://www.uptodate.com/contents/antiprotozoal-therapies/abstract/24,25\" class=\"abstract_t\">24,25</a>]. Aerosolized pentamidine used for the prophylaxis of <em>Pneumocystis </em>pneumonia in susceptible patients is associated with local adverse effects, including sore throat, oral paresthesias, metallic taste, cough, and bronchospasm.</p><p class=\"headingAnchor\" id=\"H15\"><span class=\"h1\">PYRIMETHAMINE</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Pyrimethamine-sulfadiazine is used in the treatment of toxoplasmosis. The high doses required for this treatment often result in significant folate deficiency, requiring folinic acid replacement. Abdominal symptoms and rashes are also common. (See <a href=\"topic.htm?path=toxoplasmosis-in-hiv-infected-patients\" class=\"medical medical_review\">&quot;Toxoplasmosis in HIV-infected patients&quot;</a>.)</p><p>Pyrimethamine-dapsone is used for prophylaxis of <em>Pneumocystis </em>pneumonia. (See <a href=\"topic.htm?path=epidemiology-clinical-manifestations-and-diagnosis-of-pneumocystis-pneumonia-in-hiv-uninfected-patients\" class=\"medical medical_review\">&quot;Epidemiology, clinical manifestations, and diagnosis of Pneumocystis pneumonia in HIV-uninfected patients&quot;</a> and <a href=\"topic.htm?path=treatment-and-prevention-of-pneumocystis-infection-in-hiv-infected-patients\" class=\"medical medical_review\">&quot;Treatment and prevention of Pneumocystis infection in HIV-infected patients&quot;</a>.)</p><p><a href=\"topic.htm?path=pyrimethamine-drug-information\" class=\"drug drug_general\">Pyrimethamine</a> is effective for acute treatment and maintenance suppression of <em>Isospora belli</em> infections [<a href=\"https://www.uptodate.com/contents/antiprotozoal-therapies/abstract/26\" class=\"abstract_t\">26</a>]. (See <a href=\"topic.htm?path=management-of-cystoisospora-isospora-infections\" class=\"medical medical_review\">&quot;Management of Cystoisospora (Isospora) infections&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H16\"><span class=\"h1\">QUINACRINE</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Quinacrine is an acridine dye with activity against giardiasis. It is well absorbed and may impart a yellow color to the urine and rarely to the skin or sclerae. Adverse effects include headache, dizziness, vomiting, diarrhea, and, less commonly, psychotic episodes.</p><p class=\"headingAnchor\" id=\"H17\"><span class=\"h1\">SPIRAMYCIN</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=spiramycin-united-states-available-via-fda-or-other-investigational-drug-ind-protocol-only-drug-information\" class=\"drug drug_general\">Spiramycin</a> has activity against toxoplasmosis and is an alternative to antifolates. In the setting of intrauterine infection, spiramycin is administered throughout pregnancy until delivery. (See <a href=\"topic.htm?path=toxoplasmosis-and-pregnancy\" class=\"medical medical_review\">&quot;Toxoplasmosis and pregnancy&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H18\"><span class=\"h1\">SODIUM STIBOGLUCONATE</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=sodium-stibogluconate-united-states-available-via-cdc-drug-service-investigational-drug-ind-protocol-only-drug-information\" class=\"drug drug_general\">Sodium stibogluconate</a> (sodium antimony gluconate; Pentostam) is a pentavalent antimonial parenteral solution used in the treatment of leishmaniasis [<a href=\"https://www.uptodate.com/contents/antiprotozoal-therapies/abstract/27\" class=\"abstract_t\">27</a>]. Its mechanism of action is unknown. Adverse effects include muscle pain, joint stiffness, nausea, vomiting, and, less commonly, rash and cardiac or hepatic toxicity. (See <a href=\"topic.htm?path=visceral-leishmaniasis-treatment\" class=\"medical medical_review\">&quot;Visceral leishmaniasis: Treatment&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H19\"><span class=\"h1\">SURAMIN</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=suramin-united-states-available-via-cdc-drug-service-investigational-drug-ind-protocol-only-drug-information\" class=\"drug drug_general\">Suramin</a> is a polysulfonated naphthylamine derivative of urea. The mechanism of action is not fully understood; it is thought to act by inhibition of enzymes associated with DNA metabolism and protein synthesis in trypanosomal parasites [<a href=\"https://www.uptodate.com/contents/antiprotozoal-therapies/abstract/19,28\" class=\"abstract_t\">19,28</a>]. Suramin is used for treating the early stage of East African trypanosomiasis due to <em>T. b. rhodesiense</em>. It must be given intravenously and is excreted very slowly. Adverse effects are common and can be severe, including cutaneous eruptions, vomiting, paresthesias, photophobia, peripheral neuropathy, anaphylaxis, and renal damage. (See <a href=\"topic.htm?path=african-trypanosomiasis-clinical-manifestations-diagnosis-and-treatment\" class=\"medical medical_review\">&quot;African trypanosomiasis: Clinical manifestations, diagnosis, and treatment&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H20\"><span class=\"h1\">TETRACYCLINE</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=tetracycline-drug-information\" class=\"drug drug_general\">Tetracycline</a> has activity against <em>B. coli</em> and <em>D. fragilis</em> enteric infections. (See <a href=\"topic.htm?path=balantidium-coli-infection\" class=\"medical medical_review\">&quot;Balantidium coli infection&quot;</a> and <a href=\"topic.htm?path=dientamoeba-fragilis\" class=\"medical medical_review\">&quot;Dientamoeba fragilis&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H21\"><span class=\"h1\">TINIDAZOLE</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=tinidazole-drug-information\" class=\"drug drug_general\">Tinidazole</a> has activity against amebiasis, giardiasis, and vaginal trichomoniasis and may be better tolerated than <a href=\"topic.htm?path=metronidazole-drug-information\" class=\"drug drug_general\">metronidazole</a>. (See <a href=\"topic.htm?path=intestinal-entamoeba-histolytica-amebiasis\" class=\"medical medical_review\">&quot;Intestinal Entamoeba histolytica amebiasis&quot;</a> and <a href=\"topic.htm?path=extraintestinal-entamoeba-histolytica-amebiasis\" class=\"medical medical_review\">&quot;Extraintestinal Entamoeba histolytica amebiasis&quot;</a> and <a href=\"topic.htm?path=giardiasis-treatment-and-prevention\" class=\"medical medical_review\">&quot;Giardiasis: Treatment and prevention&quot;</a> and <a href=\"topic.htm?path=trichomoniasis\" class=\"medical medical_review\">&quot;Trichomoniasis&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H22\"><span class=\"h1\">TRIMETHOPRIM-SULFAMETHOXAZOLE</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=trimethoprim-sulfamethoxazole-co-trimoxazole-drug-information\" class=\"drug drug_general\">Trimethoprim-sulfamethoxazole</a> (TMP-SMX) is the preferred treatment for <em>Pneumocystis </em>pneumonia and is used for prophylaxis against this infection in immunocompromised patients. (See <a href=\"topic.htm?path=epidemiology-clinical-manifestations-and-diagnosis-of-pneumocystis-pneumonia-in-hiv-uninfected-patients\" class=\"medical medical_review\">&quot;Epidemiology, clinical manifestations, and diagnosis of Pneumocystis pneumonia in HIV-uninfected patients&quot;</a> and <a href=\"topic.htm?path=treatment-and-prevention-of-pneumocystis-infection-in-hiv-infected-patients\" class=\"medical medical_review\">&quot;Treatment and prevention of Pneumocystis infection in HIV-infected patients&quot;</a>.)</p><p>TMP-SMX is effective in treating enteric infections with <em>Isospora belli</em> and is used as long-term maintenance therapy to prevent relapse in patients with AIDS. (See <a href=\"topic.htm?path=epidemiology-clinical-manifestations-and-diagnosis-of-cystoisospora-isospora-infections\" class=\"medical medical_review\">&quot;Epidemiology, clinical manifestations, and diagnosis of Cystoisospora (Isospora) infections&quot;</a>.)</p><p>TMP-SMX also has activity against enteric infection due to <em>Cyclospora</em>. (See <a href=\"topic.htm?path=cyclospora-infection\" class=\"medical medical_review\">&quot;Cyclospora infection&quot;</a>.)</p><p>Adverse effects are primarily due to the sulfamethoxazole and include skin, liver, and bone marrow toxicity.</p><p class=\"headingAnchor\" id=\"H4205629\"><span class=\"h1\">SUMMARY</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Antiprotozoal agents with activity against giardiasis include <a href=\"topic.htm?path=metronidazole-drug-information\" class=\"drug drug_general\">metronidazole</a>, <a href=\"topic.htm?path=nitazoxanide-drug-information\" class=\"drug drug_general\">nitazoxanide</a>, <a href=\"topic.htm?path=tinidazole-drug-information\" class=\"drug drug_general\">tinidazole</a>, furazolidone, and quinacrine. (See <a href=\"#H10\" class=\"local\">'Metronidazole'</a> above and <a href=\"#H12\" class=\"local\">'Nitazoxanide'</a> above and <a href=\"#H21\" class=\"local\">'Tinidazole'</a> above and <a href=\"#H7\" class=\"local\">'Furazolidone'</a> above and <a href=\"#H16\" class=\"local\">'Quinacrine'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Antiprotozoal agents with activity against <em>Pneumocystis</em> include <a href=\"topic.htm?path=trimethoprim-sulfamethoxazole-co-trimoxazole-drug-information\" class=\"drug drug_general\">trimethoprim-sulfamethoxazole</a>, <a href=\"topic.htm?path=atovaquone-drug-information\" class=\"drug drug_general\">atovaquone</a>, <a href=\"topic.htm?path=pentamidine-drug-information\" class=\"drug drug_general\">pentamidine</a>, and pyrimethamine-dapsone. (See <a href=\"#H22\" class=\"local\">'Trimethoprim-sulfamethoxazole'</a> above and <a href=\"#H3\" class=\"local\">'Atovaquone'</a> above and <a href=\"#H14\" class=\"local\">'Pentamidine'</a> above and <a href=\"#H15\" class=\"local\">'Pyrimethamine'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Antiprotozoal agents with activity against amebiasis include <a href=\"topic.htm?path=metronidazole-drug-information\" class=\"drug drug_general\">metronidazole</a>, <a href=\"topic.htm?path=tinidazole-drug-information\" class=\"drug drug_general\">tinidazole</a>, <a href=\"topic.htm?path=paromomycin-drug-information\" class=\"drug drug_general\">paromomycin</a>, and <a href=\"topic.htm?path=iodoquinol-drug-information\" class=\"drug drug_general\">iodoquinol</a>. (See <a href=\"#H10\" class=\"local\">'Metronidazole'</a> above and <a href=\"#H21\" class=\"local\">'Tinidazole'</a> above and <a href=\"#H13\" class=\"local\">'Paromomycin'</a> above and <a href=\"#H8\" class=\"local\">'Iodoquinol'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=tetracycline-drug-information\" class=\"drug drug_general\">Tetracycline</a> and <a href=\"topic.htm?path=iodoquinol-drug-information\" class=\"drug drug_general\">iodoquinol</a> have activity against both <em>Dientamoeba fragilis</em> and <em>Balantidium coli</em>. (See <a href=\"#H20\" class=\"local\">'Tetracycline'</a> above and <a href=\"#H8\" class=\"local\">'Iodoquinol'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The use of antiprotozoal therapies for treatment of specific protozoal infections is discussed in detail separately. (See related topics.)</p><p/></div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\"><li class=\"breakAll\">Drugs for Parasitic Infections, 3rd ed, The Medical Letter, New Rochelle, NY 2013.</li><li><a href=\"https://www.uptodate.com/contents/antiprotozoal-therapies/abstract/2\" class=\"nounderline abstract_t\">Lacey E. Mode of action of benzimidazoles. Parasitol Today 1990; 6:112.</a></li><li><a href=\"https://www.uptodate.com/contents/antiprotozoal-therapies/abstract/3\" class=\"nounderline abstract_t\">Blanshard C, Ellis DS, Tovey DG, et al. Treatment of intestinal microsporidiosis with albendazole in patients with AIDS. AIDS 1992; 6:311.</a></li><li><a href=\"https://www.uptodate.com/contents/antiprotozoal-therapies/abstract/4\" class=\"nounderline abstract_t\">Molina JM, Oksenhendler E, Beauvais B, et al. Disseminated microsporidiosis due to Septata intestinalis in patients with AIDS: clinical features and response to albendazole therapy. J Infect Dis 1995; 171:245.</a></li><li><a href=\"https://www.uptodate.com/contents/antiprotozoal-therapies/abstract/5\" class=\"nounderline abstract_t\">Weber R, Sauer B, Spycher MA, et al. Detection of Septata intestinalis in stool specimens and coprodiagnostic monitoring of successful treatment with albendazole. Clin Infect Dis 1994; 19:342.</a></li><li><a href=\"https://www.uptodate.com/contents/antiprotozoal-therapies/abstract/6\" class=\"nounderline abstract_t\">Dieterich DT, Lew EA, Kotler DP, et al. Treatment with albendazole for intestinal disease due to Enterocytozoon bieneusi in patients with AIDS. J Infect Dis 1994; 169:178.</a></li><li><a href=\"https://www.uptodate.com/contents/antiprotozoal-therapies/abstract/7\" class=\"nounderline abstract_t\">Asmuth DM, DeGirolami PC, Federman M, et al. Clinical features of microsporidiosis in patients with AIDS. Clin Infect Dis 1994; 18:819.</a></li><li><a href=\"https://www.uptodate.com/contents/antiprotozoal-therapies/abstract/8\" class=\"nounderline abstract_t\">Molina JM, Chastang C, Goguel J, et al. Albendazole for treatment and prophylaxis of microsporidiosis due to Encephalitozoon intestinalis in patients with AIDS: a randomized double-blind controlled trial. J Infect Dis 1998; 177:1373.</a></li><li><a href=\"https://www.uptodate.com/contents/antiprotozoal-therapies/abstract/9\" class=\"nounderline abstract_t\">Leder K, Ryan N, Spelman D, Crowe SM. Microsporidial disease in HIV-infected patients: a report of 42 patients and review of the literature. Scand J Infect Dis 1998; 30:331.</a></li><li><a href=\"https://www.uptodate.com/contents/antiprotozoal-therapies/abstract/10\" class=\"nounderline abstract_t\">Conteas CN, Berlin OG, Speck CE, et al. Modification of the clinical course of intestinal microsporidiosis in acquired immunodeficiency syndrome patients by immune status and anti-human immunodeficiency virus therapy. Am J Trop Med Hyg 1998; 58:555.</a></li><li><a href=\"https://www.uptodate.com/contents/antiprotozoal-therapies/abstract/11\" class=\"nounderline abstract_t\">Haile LG, Flaherty JF. Atovaquone: a review. Ann Pharmacother 1993; 27:1488.</a></li><li><a href=\"https://www.uptodate.com/contents/antiprotozoal-therapies/abstract/12\" class=\"nounderline abstract_t\">Dixon R, Pozniak AL, Watt HM, et al. Single-dose and steady-state pharmacokinetics of a novel microfluidized suspension of atovaquone in human immunodeficiency virus-seropositive patients. Antimicrob Agents Chemother 1996; 40:556.</a></li><li><a href=\"https://www.uptodate.com/contents/antiprotozoal-therapies/abstract/13\" class=\"nounderline abstract_t\">Denise H, Barrett MP. Uptake and mode of action of drugs used against sleeping sickness. Biochem Pharmacol 2001; 61:1.</a></li><li><a href=\"https://www.uptodate.com/contents/antiprotozoal-therapies/abstract/14\" class=\"nounderline abstract_t\">Kingsnorth AN. The chemotherapeutic potential of polyamine antimetabolites. Ann R Coll Surg Engl 1986; 68:76.</a></li><li><a href=\"https://www.uptodate.com/contents/antiprotozoal-therapies/abstract/15\" class=\"nounderline abstract_t\">Beauvais B, Sarfati C, Challier S, Derouin F. In vitro model to assess effect of antimicrobial agents on Encephalitozoon cuniculi. Antimicrob Agents Chemother 1994; 38:2440.</a></li><li><a href=\"https://www.uptodate.com/contents/antiprotozoal-therapies/abstract/16\" class=\"nounderline abstract_t\">Altamirano A, Bondani A. Adverse reactions to furazolidone and other drugs. A comparative review. Scand J Gastroenterol Suppl 1989; 169:70.</a></li><li><a href=\"https://www.uptodate.com/contents/antiprotozoal-therapies/abstract/17\" class=\"nounderline abstract_t\">American Academy of Pediatrics Committee on Drugs: Clioquinol (iodochlorhydroxyquin, vioform) and iodoquinol (diiodohydroxyquin): blindness and neuropathy. Pediatrics 1990; 86:797.</a></li><li><a href=\"https://www.uptodate.com/contents/antiprotozoal-therapies/abstract/18\" class=\"nounderline abstract_t\">de Andrade AL, Zicker F, de Oliveira RM, et al. Randomised trial of efficacy of benznidazole in treatment of early Trypanosoma cruzi infection. Lancet 1996; 348:1407.</a></li><li><a href=\"https://www.uptodate.com/contents/antiprotozoal-therapies/abstract/19\" class=\"nounderline abstract_t\">Wang CC. Molecular mechanisms and therapeutic approaches to the treatment of African trypanosomiasis. Annu Rev Pharmacol Toxicol 1995; 35:93.</a></li><li><a href=\"https://www.uptodate.com/contents/antiprotozoal-therapies/abstract/20\" class=\"nounderline abstract_t\">Frayha GJ, Smyth JD, Gobert JG, Savel J. The mechanisms of action of antiprotozoal and anthelmintic drugs in man. Gen Pharmacol 1997; 28:273.</a></li><li><a href=\"https://www.uptodate.com/contents/antiprotozoal-therapies/abstract/21\" class=\"nounderline abstract_t\">Castro JA, Diaz de Toranzo EG. Toxic effects of nifurtimox and benznidazole, two drugs used against American trypanosomiasis (Chagas' disease). Biomed Environ Sci 1988; 1:19.</a></li><li><a href=\"https://www.uptodate.com/contents/antiprotozoal-therapies/abstract/22\" class=\"nounderline abstract_t\">Nitazoxanide (Alinia)--a new anti-protozoal agent. Med Lett Drugs Ther 2003; 45:29.</a></li><li><a href=\"https://www.uptodate.com/contents/antiprotozoal-therapies/abstract/23\" class=\"nounderline abstract_t\">Sands M, Kron MA, Brown RB. Pentamidine: a review. Rev Infect Dis 1985; 7:625.</a></li><li><a href=\"https://www.uptodate.com/contents/antiprotozoal-therapies/abstract/24\" class=\"nounderline abstract_t\">O'Brien JG, Dong BJ, Coleman RL, et al. A 5-year retrospective review of adverse drug reactions and their risk factors in human immunodeficiency virus-infected patients who were receiving intravenous pentamidine therapy for Pneumocystis carinii pneumonia. Clin Infect Dis 1997; 24:854.</a></li><li><a href=\"https://www.uptodate.com/contents/antiprotozoal-therapies/abstract/25\" class=\"nounderline abstract_t\">Salamone FR, Cunha BA. Update on pentamidine for the treatment of Pneumocystis carinii pneumonia. Clin Pharm 1988; 7:501.</a></li><li><a href=\"https://www.uptodate.com/contents/antiprotozoal-therapies/abstract/26\" class=\"nounderline abstract_t\">Weiss LM, Perlman DC, Sherman J, et al. Isospora belli infection: treatment with pyrimethamine. Ann Intern Med 1988; 109:474.</a></li><li><a href=\"https://www.uptodate.com/contents/antiprotozoal-therapies/abstract/27\" class=\"nounderline abstract_t\">Herwaldt BL, Stokes SL, Juranek DD. American cutaneous leishmaniasis in U.S. travelers. Ann Intern Med 1993; 118:779.</a></li><li><a href=\"https://www.uptodate.com/contents/antiprotozoal-therapies/abstract/28\" class=\"nounderline abstract_t\">P&eacute;pin J, Milord F. The treatment of human African trypanosomiasis. Adv Parasitol 1994; 33:1.</a></li></ol></div><div id=\"topicVersionRevision\">Topic 489 Version 15.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul id=\"innerOutline\"><li class=\"sr-button\"><a href=\"#H4205629\"><span>SUMMARY</span></a></li><li><a href=\"#H1\" id=\"outline-link-H1\">INTRODUCTION</a></li><li><a href=\"#H2\" id=\"outline-link-H2\">ALBENDAZOLE</a></li><li><a href=\"#H3\" id=\"outline-link-H3\">ATOVAQUONE</a></li><li><a href=\"#H4\" id=\"outline-link-H4\">BENZNIDAZOLE</a></li><li><a href=\"#H5\" id=\"outline-link-H5\">EFLORNITHINE</a></li><li><a href=\"#H6\" id=\"outline-link-H6\">FUMAGILLIN</a></li><li><a href=\"#H7\" id=\"outline-link-H7\">FURAZOLIDONE</a></li><li><a href=\"#H8\" id=\"outline-link-H8\">IODOQUINOL</a></li><li><a href=\"#H9\" id=\"outline-link-H9\">MELARSOPROL</a></li><li><a href=\"#H10\" id=\"outline-link-H10\">METRONIDAZOLE</a></li><li><a href=\"#H11\" id=\"outline-link-H11\">NIFURTIMOX</a></li><li><a href=\"#H12\" id=\"outline-link-H12\">NITAZOXANIDE</a></li><li><a href=\"#H13\" id=\"outline-link-H13\">PAROMOMYCIN</a></li><li><a href=\"#H14\" id=\"outline-link-H14\">PENTAMIDINE</a></li><li><a href=\"#H15\" id=\"outline-link-H15\">PYRIMETHAMINE</a></li><li><a href=\"#H16\" id=\"outline-link-H16\">QUINACRINE</a></li><li><a href=\"#H17\" id=\"outline-link-H17\">SPIRAMYCIN</a></li><li><a href=\"#H18\" id=\"outline-link-H18\">SODIUM STIBOGLUCONATE</a></li><li><a href=\"#H19\" id=\"outline-link-H19\">SURAMIN</a></li><li><a href=\"#H20\" id=\"outline-link-H20\">TETRACYCLINE</a></li><li><a href=\"#H21\" id=\"outline-link-H21\">TINIDAZOLE</a></li><li><a href=\"#H22\" id=\"outline-link-H22\">TRIMETHOPRIM-SULFAMETHOXAZOLE</a></li><li><a href=\"#H4205629\" id=\"outline-link-H4205629\">SUMMARY</a></li><li><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li class=\"plainItem\"><a href=\"topic.htm?path=african-trypanosomiasis-clinical-manifestations-diagnosis-and-treatment\" class=\"medical medical_review\">African trypanosomiasis: Clinical manifestations, diagnosis, and treatment</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=anthelminthic-therapies\" class=\"medical medical_review\">Anthelminthic therapies</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=antimalarial-drugs-an-overview\" class=\"medical medical_review\">Antimalarial drugs: An overview</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=babesiosis-clinical-manifestations-and-diagnosis\" class=\"medical medical_review\">Babesiosis: Clinical manifestations and diagnosis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=balantidium-coli-infection\" class=\"medical medical_review\">Balantidium coli infection</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=chagas-disease-antitrypanosomal-drug-therapy\" class=\"medical medical_review\">Chagas disease: Antitrypanosomal drug therapy</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=chagas-gastrointestinal-disease\" class=\"medical medical_review\">Chagas gastrointestinal disease</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=chagas-heart-disease-treatment-and-prognosis\" class=\"medical medical_review\">Chagas heart disease: Treatment and prognosis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=cyclospora-infection\" class=\"medical medical_review\">Cyclospora infection</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=dientamoeba-fragilis\" class=\"medical medical_review\">Dientamoeba fragilis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=epidemiology-clinical-manifestations-and-diagnosis-of-cystoisospora-isospora-infections\" class=\"medical medical_review\">Epidemiology, clinical manifestations, and diagnosis of Cystoisospora (Isospora) infections</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=epidemiology-clinical-manifestations-and-diagnosis-of-pneumocystis-pneumonia-in-hiv-uninfected-patients\" class=\"medical medical_review\">Epidemiology, clinical manifestations, and diagnosis of Pneumocystis pneumonia in HIV-uninfected patients</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=epidemiology-clinical-manifestations-and-diagnosis-of-cryptosporidiosis\" class=\"medical medical_review\">Epidemiology, clinical manifestations, and diagnosis of cryptosporidiosis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=extraintestinal-entamoeba-histolytica-amebiasis\" class=\"medical medical_review\">Extraintestinal Entamoeba histolytica amebiasis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=giardiasis-treatment-and-prevention\" class=\"medical medical_review\">Giardiasis: Treatment and prevention</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=intestinal-entamoeba-histolytica-amebiasis\" class=\"medical medical_review\">Intestinal Entamoeba histolytica amebiasis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=management-of-cystoisospora-isospora-infections\" class=\"medical medical_review\">Management of Cystoisospora (Isospora) infections</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=metronidazole-an-overview\" class=\"medical medical_review\">Metronidazole: An overview</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=microsporidiosis\" class=\"medical medical_review\">Microsporidiosis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=overview-of-prevention-of-opportunistic-infections-in-hiv-infected-patients\" class=\"medical medical_review\">Overview of prevention of opportunistic infections in HIV-infected patients</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=toxoplasmosis-and-pregnancy\" class=\"medical medical_review\">Toxoplasmosis and pregnancy</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=toxoplasmosis-in-hiv-infected-patients\" class=\"medical medical_review\">Toxoplasmosis in HIV-infected patients</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=treatment-and-prevention-of-pneumocystis-infection-in-hiv-infected-patients\" class=\"medical medical_review\">Treatment and prevention of Pneumocystis infection in HIV-infected patients</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=trichomoniasis\" class=\"medical medical_review\">Trichomoniasis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=visceral-leishmaniasis-treatment\" class=\"medical medical_review\">Visceral leishmaniasis: Treatment</a></li></ul></div></div>","javascript":null}